All In Biotech

Drug Trial Radar · NCT01448109

ADjunctive coRticosteroid trEatment iN criticAlly ilL Patients With Septic Shock

A Randomised Blinded Placebo Controlled Trial of Hydrocortisone in Critically Ill Patients With Septic Shock

Last checked: Nov 19, 2026Latest source record: Dec 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 3,800 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,800

Actual

Start

Jun 13, 2012

Primary completion

Oct 22, 2017

Study completion Nov 20, 2017

Sponsor

Lead sponsor
The George InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Health and Medical Research Council, Australia; Australian and New Zealand Intensive Care Society Clinical Trials Group
First posted
Oct 7, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out whether adult patients admitted to the Intensive Care Unit with septic shock who are given hydrocortisone compared to placebo (a dummy solution), will have an improved rate of survival 90 days later. Septic shock is the result of an infection, which triggers a complex response by the body (the inflammatory response) that causes a decrease in blood pressure and subsequently one or more organ systems to fail when blood supply to these organs is reduced. This may result in poor recovery and death. About a quarter of the people who suffer septic shock that is not rapidly reversed, will die. When patients are admitted to Intensive Care with sepsis and/or septic shock they receive a number of therapies. These include fluids given through a drip, antibiotics, drugs to boost your blood pressure and other organ systems. In addition to these therapies, steroids (hydrocortisone) are sometimes administered. Whether steroids are useful or not in the treatment of severe infections has been studied for more than 50 years. Previous research has suggested that the use of low dose steroid may have shortterm benefits in improving the circulation. However, there is no agreement amongst doctors around the world about whether treatment with or without low dose steroids improves the overall recovery and survival in patients with septic shock. This study would allow doctors to make informed decisions about whether the addition of low dose steroid therapy is better for patients with septic shock in intensive care. The study will include 3800 intensive care patients who have septic shock. Each enrolled patient will be randomised to receive either Hydrocortisone 200mg or placebo daily for 7 days as a continuous intravenous infusion while in intensive care. The patient will be followed for 90 days. If the patient is discharged prior to 90 days a telephone call will be made for the followup information. At six months the patient will be contacted again for completion of a quality of life questionnaire.

Conditions

  • Septic Shock

Interventions

  • HydrocortisoneDrug

    Hydrocortisone 100mg vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion at rate of 200mg/per day for 7 days.

  • Sterile air filled vialDrug

    the "sterile air filled vial" (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion. 2 sterile air filled vials per day for 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All cause mortality at 90 days after randomisationTime frame: 90 days after randomisation

Locations

70 sites in 5 countries. Site status is shown where the registry gives one.

  • Blacktown Hospital

    Blacktown, New South Wales, Australia

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • St Vincent's Hospital

    Darlinghurst, New South Wales, Australia

  • Gosford Hospital

    Gosford, New South Wales, Australia

  • St George Hospital

    Kogarah, New South Wales, Australia

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • John Hunter Hospital

    Newcastle, New South Wales, Australia

  • Nepean Hospital

    Penrith, New South Wales, Australia

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • The George Institute for Global Health

    Sydney, New South Wales, Australia

  • Tamworth Rural Referral Hospital

    Tamworth, New South Wales, Australia

  • Tweed Heads District Hospital

    Tweed Heads, New South Wales, Australia

  • Calvary Mater Hospital (Newcastle)

    Waratah, New South Wales, Australia

  • Wollongong Hospital

    Wollongong, New South Wales, Australia

  • Royal Darwin Hospital

    Darwin, Northern Territory, Australia

  • Wesley Hospital

    Auchenflower, Queensland, Australia

  • Prince Charles Hospital

    Brisbane, Queensland, Australia

  • Mater Health Services

    Brisbane, Queensland, Australia

  • Gold Coast University Hospital

    Gold Coast, Queensland, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia

  • Ipswich Hospital

    Ipswich, Queensland, Australia

  • Logan Hospital

    Logan City, Queensland, Australia

  • Mackay Base Hospital

    Mackay, Queensland, Australia

  • Nambour Hospital

    Nambour, Queensland, Australia

  • Redcliffe Hospital

    Redcliffe, Queensland, Australia

  • Toowoomba Hospital

    Toowoomba, Queensland, Australia

  • Townsville Hospital

    Townsville, Queensland, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Lyell McEwin Hospital

    Elizabeth Vale, South Australia, Australia

  • The Queen Elizabeth Hospital

    Woodville South, South Australia, Australia

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia

  • Bendigo Hospital

    Bendigo, Victoria, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Northern Hospital

    Epping, Victoria, Australia

  • St Vincent's Hospital (Melbourne)

    Fitzroy, Victoria, Australia

  • Footscray Hospital

    Footscray, Victoria, Australia

  • Geelong Hospital (Barwon Health)

    Geelong, Victoria, Australia

  • Austin Hospital

    Heidelberg, Victoria, Australia

Showing 40 of 70 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.